Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Contineum Therapeutics, Inc. on June 26, 2025. The meeting was conducted virtually. As of the record date of April 28, 2025, there were 19,142,377 shares of Class A common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes are reported in this filing. The document details the outcomes of two stockholder proposals:
- Proposal 1 (Election of Directors): Stockholders elected three Class I directors (Sarah Boyce, Troy Ignelzi, and Olivia Ware) to serve until the 2028 Annual Meeting.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the final voting results for the three director nominees, noting that Troy Ignelzi received the highest number of "For" votes (13,227,301).
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2025 fiscal year.
- Note the number of broker non-votes (2,050,305) recorded for the director election, which did not affect the outcome but indicates significant institutional holdings.
- Review the company's upcoming 10-K or 10-Q filings for the financial metrics absent from this 8-K.